Fred Hutchinson Cancer Center's Specialized Program of Research Excellence (SPORE) in Lung Cancer was awarded by the National Cancer Institute in August of 2019 to support groundbreaking research that translates directly into improved prevention, detection, and treatment for patients. SPORE awards are intended to prevent new cases of cancer, as well as improve survival and quality of life for current patients. Key elements of the program are interdisciplinary collaboration, resource sharing, and inclusion of patient advocates on the research team.
The Fred Hutch Lung SPORE will support three upcoming clinical trials opening for patient enrollment in 2021. Our clinical trials will feature new treatments in immunotherapy, such as checkpoint inhibitors and cancer vaccines, intended to help patients’ own immune systems fight their cancer more effectively.
Our Lung SPORE investigators are treating physicians at Fred Hutchinson Cancer Center and University of Washington.
Dr. McGarry Houghton
The inclusion of patient advocates is a crucial element of our Lung SPORE. Our experienced patient advocates provide assurance that our clinical trials are designed to provide a meaningful patient impact. They also assist with outreach to the lung cancer patient community and assist with recruitment of patients to our research protocols and clinical trials.
Ms. Freeman-Daily is a metastatic lung cancer patient diagnosed in May 2011. Her self-advocacy enabled her to obtain biomarker testing that found the ROS1 gene alteration driving her tumor. This led her to enroll in a clinical trial at the University of Colorado, where she became a patient advocate on their Lung SPORE. Janet, a retired Boeing engineer in the Seattle area, now focuses on translating the science and experience of lung cancer for others. She blogs at Gray Connections, is a leader of The ROS1ders patient group, co-hosts #LCSM (Lung Cancer Social Media) Chat on Twitter, speaks at international cancer conferences, and is helping to develop the IASLC STARS (Supportive Training for Advocates in Research and Science) program.
Ms. Moffitt is a >15-year survivor of Stage IV NSCLC squamous cell. She received her treatment at the Mayo Clinic in Rochester and initially became involved in advocacy programs there. Since that time, Pam has become involved in numerous review panels, including for the Department of Defense and the FDA. She is particularly interested in the informed consent process. Ms. Moffitt also is an advocate of lung cancer early detection programs and maintains an interest in the emotional cost that undiagnosed lung cancer can have on patients enrolled in lung cancer screening protocols.
Prospective lung cancer patients, their families and their caregivers need information on cancer, treatment options, access to care and supportive services. The resources listed below are a good place to start, along with Fred Hutch's Patient Treatment & Support information.